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ABSTRACT:  The present review article summarizes the current state radiolabeled 
nanoparticles for molecular imaging applications mainly targeting cancer. Due to their 
enormous flexibility, and versatility the radiolabeled nanoparticles have shown their 
potential in the diagnosis and therapy. As the matter of fact, these radiolabeled imaging 
agents enable the visualization of the cellular function and the follow-up of the molecular 
process in living organisms. Moreover, the rapidly advancing field of nanotechnology has 
provided various innovative radionuclides and delivery systems, such as liposomes, 
magnetic agents, polymers, dendrimers, quantum dots, and carbon nanotubes to cope up 
with the hurdles which have been posed by various disease states. 
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INTRODUCTION
ᴪ 
 
Nuclear imaging is a branch of medical imaging 
that uses radioisotopes for the study of the 
physiology and the metabolism of the body.
1 This 
is achieved by administrating radiopharmaceuticals 
to the patients and imaging the emitted radiation. 
The acquired information is useful not only for 
diagnostic purposes, such as detection of functional 
abnormalities or early identification of tumors, but 
also can be very helpful in therapy planning and 
follow-up.  The two most common types of nuclear 
medicine studies are Positron Emission 
Tomography (PET) and Single Photon Emission 
Computed Tomography (SPECT).  
Positron Emission Tomography (PET) is an 
imaging technique which detects pairs of gamma 
rays emitted indirectly by a positron-emitting 
radionuclide introduced into the body.
1 Hence, a 
radioisotope which undergoes positron emission 
decay (PET) emits a positron that encounters with 
an electron, producing a pair of gamma photons 
moving in opposite directions. These gamma 
photons are detected by the photomultiplier tubes 
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or silicon avalanche photodiodes place in the 
opposite direction at 180
◦. Basically, PET imaging 
depends on simultaneous detection of the pair of 
photons and those photons which do not arrive in 
pairs are ignored. These photons are then detected 
by the scanner which can estimate the density of 
positron annihilations in a specific area. When 
enough interactions and annihilations have 
occurred, the density of the original molecule may 
be measured in that area. Typically 
11C, 
13N, 
15O, 
18F, 
64Cu, 
62Cu, 
124I, 
76Br, 
82Rb, 
68Ga, and 
18F can be 
used with 
11C, 
13N, 
15O, 
18F being the first choice. 
Table 1 and 2 show various radionuclides 
commonly used for tumor imaging along with their 
production techniques, emission types and 
respective half life. Of the various radionuclides 
listed in table 1 and 2 
18F nuclide is more preferred 
radionuclide due to the lowest energy. On the other 
hand, SPECT is similar to PET which utilizes 
radiotracers that emit a single or multiple photons 
which are not simultaneously detected. The 
photons emitted by the nucleus, after traversing the 
human body, are detected and registered as a 
projection (2D distribution) by the scintillation 
camera. The projections are re-arranged as 
sinograms for tomographic reconstructions. Mody et al / Nanoparticles in Nuclear Imaging 
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Table 1: Common β emitter Radionuclides for tumor PET imaging along with their production 
techniques, emission types, respective half life and biomedical application
2, 3 
 
Radionuclide Emission 
type 
Half-life Emax   
(keV) 
Mode of 
Generation 
Biomedical 
Application 
18F  Positron  1.83 h  640  Cyclotron  Glucose metabolism, 
Hypoxic tissue, 
Nicotinic acetylcholine 
receptors
 
11C Positron  20.4  min  960  Cyclotron  Biosynthesis  of 
phospholipids, Choline 
receptors
 
13N  Positron  9.96 min  1190  Cyclotron  Blood flow
 
15O  Positron  2.07 min  1720  Cyclotron  Oxygen metabolism, 
Blood flow, Blood 
volume. 
64Cu  Positron  762 mins  0.655  Cyclotron  Tumor detection 
68Ga  Positron  78.3 h  93, 184, 300, 393  Cyclotron 
 Tumor detection
 
Table 2: Common γ emitter radionuclides for SPECT imaging along with their production techniques, 
emission types, respective half life and biomedical application 
2, 3 
 
Radionuclide Emitter  Half  Life 
(h) 
Emax 
(KeV) 
Mode of 
Generation 
Biomedical Application 
99mTc  γ 6.0    140 
99Mo generator Tumor imaging
 
201Tl  γ 73  70-80; 
135;167 
Cyclotron Tumor  imaging 
67Ga  γ 78  93.5;184.5; 
296; 388 
Cyclotron Tumor  imaging 
111In  γ  67.2 h  171, 245  Cyclotron  Imaging and radiotherapy 
123I  γ 13.2  h  159    Cyclotron  Thyroid
 
131I  γ 
(81.2%), 
β 
8.0 days  284, 364, 637  Cyclotron  Thyroid
 
 
Even though, SPECT is much cheaper than PET, 
cost of making these instrument is one of the major 
disadvantages of nuclear imaging. Conversely, both 
of these nuclear imaging does have many 
advantages though. First, the sensitivity of a typical 
PET scanner is very high and can detect between 
10
−11 mol/L to 10
−12 mol/L concentrations. 
Secondly, PET images biochemical or physiologic 
phenomena in contrast to computed tomography 
(CT) which show anatomic detail. Because of this, 
PET offers substantial advantages over other 
anatomic imaging modalities.  
In general, majority of the radionuclides used in 
PET imaging are produced by cyclotrons either on 
site or at a site near the scanner.
1 Once the 
radiolabeled isotopes are produced its replacement Mody et al / Nanoparticles in Nuclear Imaging 
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can be carried out via isotopic substitution or non 
isotopic substitution. Since 
12C, 
14N and 
16O being 
part of the biomolecules their replacement with 
their respective isotopes is isotopic substitution, 
whereas the radiolabeling with 
18F is mainly the 
substitution of a hydrogen atom or hydroxyl group 
by a fluorine atom.
4 Not being part of 
biomolecules, the replacement of the 
18F induces 
only minimum steric perturbations.
5 In addition, the 
strong electronic property of fluorine atom 
modulates the lipophilicity and biological 
characteristics of the radiopharmaceuticals as 
compared to the nonfluorinated analogues as shown 
by Zang and Coworkers.
4, 6  The longer half-life of 
18F (110 min) allows complex radio synthesis, and 
longer in vivo investigation. As the matter of fact, 
current PET imaging techniques utilizes 
isotopically labeled Fluorodeoxyglucose (FDG) as 
the imaging agent as the malignant cells have 
higher rates of aerobic glycolysis than normal 
tissues. Thus, the malignant cell utilizes more 
glucose to meet its energy needs. Fortunately, 
while Fluorodeoxyglucose (FDG) is not an ideal 
imaging agent as some tumors show poor FDG 
metabolism than some benign processes, it works 
very well in most malignant tumors of clinical 
importance.
7-9 Hence, FDG uptake reflects the 
culmination of complex and incompletely 
understood biological processes that affect 
glycolysis in a specific tumor.  Infact, use of 
19F 
labled FDG have shown the its high potential with 
PET for detection and staging of the breast 
cancer.
10,11 Although there are no ideal 
radiopharmaceuticals, the following characteristics 
should direct the proper choice of an adequate 
compound: its concentration in the target organ or 
tissue should be higher than in non-target regions; 
the binding to the radionuclide should be strong 
enough for allowing the completion of the study; 
the radiation dose delivered to the patients should 
be as low as reasonably possible without degrading 
the diagnostic quality of the images; their 
preparation should be simple, convenient, fast and 
cost-effective; and they should interfere as least as 
possible with the normal physiological conditions 
of the patients. More often, the drug delivery 
carriers in diagnostics and therapeutics offers a 
major challenge on terms of the low drug 
bioavailability within cancer cells and the high 
toxicities to normal organs
12,13. Moreover, to 
maximize the therapeutic index and to minimize 
the toxicity of radionuclides used in imaging, it is 
very important to increase the selectivity of 
radionuclides to the site of action especially on the 
tumors cells. These challenges have been addressed 
by the development of novel nanoparticulated 
system including iron-oxide nanoparticles, gold 
nanoparticles, liposomes, emulsions, dendrimers, 
and nanotubes.
14 In addition, to maximize the 
therapeutic index and to minimize the toxicity of 
radionuclides used in imaging these novel systems 
are developed so that they range in particle size 
between 10-500 nm, seldom exceeding 700 nm.
15 
Thus, this review article focuses on radiolabeled 
nanoparticulated systems which have shown the 
future in the field of cancer diagnosis and 
therapeutics assisted via nuclear imaging. 
 
NANOPARTICLES IN NUCLEAR IMAGING 
 
Nanoparticles are long known to be ideal 
candidates for targeted drug delivery and imaging. 
Hence various approaches have been put forth for 
the modification of the nanoparticles to include 
various radionuclides rendering them available for 
nuclear imaging. The nano size of these particles 
allows various communications with biomolecules 
on the cell surfaces and within the cells in way that 
can be decoded and designated to various 
biochemical and physiochemical properties of these 
cells.
14,15 In an effort to utilize nanoparticles at their 
maximum potential, more specific targeting 
systems are designed to recognize the targeted cells 
such as cancer cells. This can be achieved by 
conjugating the nanoparticle with an appropriate 
ligand which has a specific binding activity with 
respect to the target cells. In addition, nanoparticles 
provide a platform to attach multiple copies of 
therapeutic substance on it and hence increase the 
concentration of therapeutic and diagnostic 
substances at the pathological site. Once targeted 
(active or passive), these nanocarriers can be 
designed in a way to facilitate them to act as 
imaging probes.
16  Hence, these so called 
“molecular imaging probes” can non-invasively 
provide valuable information about differentiate 
abnormalities in various body structures and organs 
to determine the extent of disease, and evaluate the 
effectiveness of treatment.
14 T h u s  i n  s h o r t ,  
molecular imaging enables the visualization of the 
cellular function and the follow-up of the molecular 
process in living organisms without perturbing 
them.
17 These advances in the field of 
nanotechnology have opened endless opportunities 
for molecular diagnostics and therapy.
18  However, 
synthesizing these nanocarriers with stealth 
characteristics with improved in vivo targeting 
capabilities are the major challenges of applying 
nanoparticles to delivery of drugs or 
radionuclides.
19-21 Fortunately, these affairs has 
been well tackled by the rapidly advancing field of 
cancer nanotechnology by providing various 
innovative radionuclides and delivery systems, 
such as liposomes, magnetic agents, polymers, 
dendrimers, quantum dots, and carbon 
nanotubes.
13,22-38 These novel systems have 
enormously helped to rally the transport of 
radionuclides to tumor sites 
2,12,13,19,20,39. In effect, 
the development of polymeric nanoparticulate 
systems encompassing long lived radionuclide such Mody et al / Nanoparticles in Nuclear Imaging 
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as 
3H, 
14C, 
125I is long known.
20,40-42 These 
radionuclides still remain resource for researchers 
studying new materials. As the matter of fact, it is 
estimated that approximately 240 nano-enabled 
products entered pharmaceutical research pipelines 
in 2006.
21,43 These nanocarrier systems could 
provide the delivery platforms needed for 
improving the delivery of radionuclides to tumor 
sites by targeted delivery of drugs to the tumor site 
thus reducing their toxic side-effects.
44-49 
Various approaches are used for labeling 
radionuclides are the surface labeling of the 
nanoparticle after encapsulation or encapsulating a 
radiolabeling nanoparticle. However, the 
nanoparticles conjugated with bifunctional 
chelators and targeting ligands are particularly 
useful because their higher surface area which 
allows a higher number of targeting residues and 
radionuclides per particle. This relays higher 
affinity and specific activity of the molecules 
towards the target cells.
20 Thus, the surface labeling 
the nanoparticle has shown a wide of interest to the 
molecules that may be directly coupled via a 
suitable coupling strategy. Generally, linker should 
be readily labelable with the radionuclide, the label 
should be sufficiently stable under in vivo 
conditions without any non-specific interactions in 
the organism.
50 
Various radionuclides with functional characteristic 
has been designed and tagged onto a nanoparticle.  
In fact, Hallahan et al  developed 
131I labeled 
albumin nanaoparticles targeted on the integrin 
receptors for the imaging of the tumor blood 
vessles.
51 They used the peptide that included the 
amino acid sequence RGDGSSV. This peptide 
binds to integrins within the tumor 
microvasculature. It was demonstrated that the 
radiopharmaceuticals were localized to irradiated 
tumors by use of α2bβ3 ligands conjugated to 
nanoparticles and liposomes. In a similar approach 
Hu et al presented perfluorocarbon nanoparticles 
labelled with iodine conjugated to intergrin seeking 
peptide sequence.
51,52 In both studies tumor active 
targeting, intra-tumoral radioactivity uptake 
reached high levels up to 90% of total body 
radioactivity.
2, 52 
Likewise, Plotkin and Coworkers developed O-(2-
[
18F]fluoroethyl)-L-tyrosine (FET) based amino 
acid tracer for targeting the nanoparticles to be 
imaged by PET. Results showed that PET imaging 
increased the estimation of the gross tumor volume 
by 22-28% and are highly valuable for defining the 
target volume for the nano cancer therapy.
53 Other 
methods of labeling a nanoparticle involve the 
conjugation of methalchelate to nanoparticle. 
Rossin et al evaluated the use of PET to 
noninvasively image the lung uptake and 
distribution of NPs coated with an anti-ICAM 
antibody and radiolabelled 
64Cu-DOTA (DOTA is 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 
acid).
54 Results showed that even after 24 hours of 
injection the lungs of mice injected with 
radiolabeled
 anti-ICAM NPs were clearly imaged 
by microPET.
54 Similarly, in an attempt to improve 
the blood circulation time, Fukukawa and 
coworkers have reported synthesis of novel core-
shell star copolymers having a poly(ethylene 
glycol) outer shell, a hydrophilic inner shell of N,N-
dimethylacrylamide bearing reactive functional 
groups, and a central hydrophobic core N-
acryloxysuccinimide. Functionalization of these 
polymeric nanoparticles with a DOTA-ligand 
capable of chelating radioactive 
64Cu nuclei 
enabled in vivo positron emission tomography 
(PET) imaging. The particle size of these 
nanoparticles ranged from 3-70 nm as calculated by 
DLS. Further, the results indicated that 
nanoparticles with increasing PEG shell show 
increased blood circulation and suggesting 
application as in vivo carriers for imaging, 
targeting, and therapeutic groups.
55  
Similar to these conjugated radiolabeled doping of 
radiolabel into nanoparticles or the use of doped 
radiolabeled nanoparticles is seen as another way 
of optimizing lead molecules on to the target cells. 
Doped nanoparticles often provide enormous 
advantages by reducing the direct impact of 
radionuclide onto the benign tissue. Thus, even 
with these advances in the synthesis of 
nanoparticle, the inability to detect small 
macroscopic disease (<0.5 cm)  and the lower 
sensitivity of  for accurate staging are some of the 
disadvantages of nuclear imaging.
56,57 The most 
impeding factors to the PET studies is that the 
images obtained with PET are of substantially 
lower resolution than, for example, those of MRI. 
To add, PET is generally poor at delineating 
anatomic details. This lack of detail results in poor 
localization of lesions and poor demarcation of 
lesion borders. Moreover, lesions are often 
complex, with some portions more metabolically 
active than others.
58 The operating cost and the side 
effects from radiation have always been a major 
issue. 
 
CONCLUSION 
 
Radiopharmaceuticals are long being explored as 
agents for the delimitation of disease, whereas, the 
advent of nanoparticles has accelerated this motion 
and has emerged as the front runner to aid its 
diagnosis and treatment. Despite the fact, enormous 
research has been done towards developing novel 
nanoparticulated imaging systems, the role of 
nanoparticle in diagnosis is far from over. 
Moreover, in coming years they will continue to be 
modified, derivatized and functionalized for its 
advanced application in the field of 
radiopharmaceuticals due to great deal of efforts 
from the scientist all over the world. Mody et al / Nanoparticles in Nuclear Imaging 
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